Galderma Posts Record Sales and Raises 2026 Growth Outlook
Swiss dermatology and aesthetics company Galderma Group AG (SIX: GALD) reported record nine-month net sales of $4.765 billion, up 25.1% at constant currency year over year. The company also raised its full-year 2026 sales growth guidance for the second consecutive quarter.
Third-quarter revenue reached $1.63 billion, exceeding analyst forecasts of $1.55 billion by more than $80 million. Growth across Galderma’s business divisions included:
- Therapeutic Dermatology: Up 64.4% at constant currency, led by Nemluvio, its treatment for atopic dermatitis and chronic pruritus. The product generated $302 million in Q3 sales.
- Injectable Aesthetics: Up 13.2%.
- Dermatological Skincare: Up 16.2%.
Following the strong performance, Galderma raised its full-year 2026 net sales growth guidance to 22.5–23.5% at constant currency, from its previous range of 19–21%. Its shares rose more than 7% after the announcement.
CEO Flemming Ornskov cited “robust demand for our differentiated, premium portfolio” as a key growth driver. The company maintained its Core EBITDA margin target of approximately 26%. With momentum across aesthetics and medical dermatology, Galderma continues to establish itself as one of the world’s fastest-growing beauty and health companies.